Abstract Next-generation HER2-targeted therapies including tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) improve survival of HER2-positive cancer patients. However, mechanisms of primary and acquired resistance remain unclear. Here, we reported that primary HER2-specific targeted therapy (tucatinib) resistant or sensitive breast cancers derived from clinical trial patients exhibited differential protein profiles.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mingxi Lin
Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases
Abstract Triple-negative breast cancer (TNBC) brain metastases (BrMs) remain a therapeutic challenge. We depict the discrepancies between primary tumors and BrMs, and examine patient-matched cerebrospinal fluid and plasma to provide detailed profiles of BrMs’ metabolic microenvironment. High-throughput in vivo loss of function CRISPR screens identify NDUFB9 (NADH: Ubiquinone Oxidoreductase Subunit B9) as a brain-specific metabolic vulnerability.
Efficacy of trastuzumab deruxtecan in HER2-positive and HER2-low metas
Yuxin Yan,1,2 Yizi Jin,1,2 Mingxi Lin,1,2 Ceng Zeng,1,2 Qing Guo,1,2 Teng Zhou,1,2 Dou Dou Li,3 Jian Zhang1,4 1Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 2Department of Breast and Urinary Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 3School of Clinical Medicine, Shanghai University of Medicine & Health Sciences, Shanghai, People’s Republic of China; 4Phase I Unit, Fudan University...
HER2‐low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis
CONFLICT OF INTEREST STATEMENT Jiong Wu reports grants/contracts from AstraZeneca, F. Hoffmann-La Roche Ltd., the National Natural Science Foundation of China, and Pfizer outside the submitted work. Wentao Yang reports personal fees from AstraZeneca, Daiichi-Sankyo, and Roche outside the submitted work. The remaining authors declared no conflicts of interest. Supporting Information Filename Description cncr35101-sup-0001-suppl-data.pdf1.4 MB Supplementary Material REFERENCES 1, .
Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
Introduction Bone is the predominant metastatic site for breast cancer. Between 39.0% and 71.4% of patients with metastatic breast cancer (MBC) develop bone metastasis during the course of the disease.1 Complications of bone metastasis include pathological fractures, spinal cord compression, and hypercalcemia,2 all of which can greatly impair the quality of life of the patient. Breast cancer with bone metastases remains virtually an incurable disease.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mingxi
Contact Mingxi, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack